- HK$84.10bn
- HK$79.10bn
- CNY3.06bn
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
HK's Akeso rallies after AstraZeneca invests $2 billion in Summit, backs ivonescimab
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
Factbox: US drugmakers turn to China for licensing deals
Brief: Akeso Says Ivonescimab Meets Os Key Secondary Endpoint In Harmoni-2 Study
Brief: Ivonescimab Meets Overall Survival Key Secondary Endpoint In Interim Analysis Of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant And Clinically Meaningful Benefit Versus Pembrolizumab In First-Line Pd-L1-Positive Nsclc
CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial
China's Akeso jumps on progress of immunotherapy drug for cancer treatment
Brief: Akeso Says Ivonescimab Plus Chemo Meets Primary Endpoint
Brief: Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy In First-Line Biliary Tract Cancer Harmoni-Gi1 Meets Primary Endpoint
Akeso climbs after China regulator nod for new lung cancer drug application
Brief: Akeso Says NMPA Approves Ivonescimab For 1L Treatment Of SQ-NSCLC
Summit gains after partner Akeso secures China nod for lung cancer combo
Summit drops as concerns over older patients cloud cancer trial data (updated)